Syros Pharmaceuticals
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Syros Pharmaceuticals sits in the upper quartile of US sponsors by registered trial count (#2,411 of 15,742 sponsors by registered trial count).
Syros Pharmaceuticals: 5 sponsored US clinical trials, none currently recruiting.
Syros Pharmaceuticals sponsors 5 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 2 completed. 1 of these trials are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Pancreatic Cancer, with 1 trials.
Upper-quartile sponsor footprint
Syros Pharmaceuticals sits in the upper quartile of the sponsor corpus (#2,411 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Indexed trials (enrollment closed)
5 total, page 1 of 1
Tamibarotene Plus Venetoclax/Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
NCT04905407
Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome
NCT04797780
A Study of SY 5609, a Selective CDK7 Inhibitor, in Advanced Solid Tumors
NCT04247126
A Study of SY-1365 in Adult Patients With Advanced Solid Tumors
NCT03134638
A Biomarker-Directed Phase 2 Trial of Tamibarotene (SY-1425) in Participants With Acute Myeloid Leukemia or Myelodysplastic Syndrome
NCT02807558
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 2 |
| Phase 3 | 1 |
Therapeutic Areas
How the Syros Pharmaceuticals early-phase archive is shaped
5 indexed studies, none listed as recruiting (0% open); 2 completed (40%).
Phase mix: 1 late (III/IV) vs 4 early (I/II) (early-phase heavy).
Top condition: Pancreatic Cancer (1 trial), 3 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Syros Pharmaceuticals: archived-pipeline peers nationwide
Peers matched on 5 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Syros Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 5 archived trials
- 4YouandMe · 5 trials · 0% recruiting
- Abbott Rapid Dx · 5 trials · 0% recruiting
- Access Business Group · 5 trials · 0% recruiting
- Acera Surgical · 5 trials · 20% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Syros Pharmaceuticals page
5 registered trials is a research-attention snapshot, not an endorsement of Syros Pharmaceuticals or any single study.
- None of Syros Pharmaceuticals's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Pancreatic Cancer is the condition Syros Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Pancreatic Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Syros Pharmaceuticals pipeline card: 5 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.